Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 25;17(5):sfae122.
doi: 10.1093/ckj/sfae122. eCollection 2024 May.

The effect of COVID-19 vaccination on kidney function and HLA antibody formation in patients with end-stage kidney disease and on kidney replacement treatment

Céline Imhof  1 , A Lianne Messchendorp  1 , Laura B Bungener  2 , Bouke G Hepkema  2 , Marcia M L Kho  3 , Marlies E J Reinders  3 , Frederike J Bemelman  4 , Luuk B Hilbrands  5 , Ron T Gansevoort  1 , Jan Stephan F Sanders  1 ; RECOVAC Consortium
Collaborators, Affiliations

The effect of COVID-19 vaccination on kidney function and HLA antibody formation in patients with end-stage kidney disease and on kidney replacement treatment

Céline Imhof et al. Clin Kidney J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1:
Figure 1:
Kidney-related outcomes after COVID-19 vaccination. (a) Heatmap with changes in specific HLA antibodies of positive patients per patient group and class. Alphabetic letters are the individuals whose characteristics are presented in Table S6. Estimated GFR slope before and after mRNA-1273 COVID-19 vaccination in (b) CKD G4/5 patients and (c) KTR. Change in eGFR slope was calculated by segmented mixed effects linear regression. Dotted lines represent the first and second vaccination. BCM, background corrected mean fluorescence intensity.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Al Jurdi A, Gassen RB, Borges TJet al. . Non-invasive monitoring for rejection in kidney transplant recipients after SARS-CoV-2 mRNA vaccination. Front Immunol 2022;13:1–14. 10.3389/fimmu.2022.838985 - DOI - PMC - PubMed
    1. Kho MML, Reinders MEJ, Baan CCet al. . The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Nephrol Dial Transplant 2021;36:1761–4. Published online 2021. 10.1093/ndt/gfab186 - DOI - PMC - PubMed
    1. Sanders JSF, Bemelman FJ, Messchendorp ALet al. . The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation 2022;106:821–34. 10.1097/TP.0000000000003983 - DOI - PMC - PubMed
    1. Kho MML, Messchendorp AL, Frölke SCet al. . Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial. Lancet Infect Dis 2023;23:307–19. 10.1016/S1473-3099(22)00650-8 - DOI - PMC - PubMed
    1. Stringer D, Gardner L, Shaw Oet al. . Optimized immunosuppression to prevent graft failure in renal transplant recipients with HLA antibodies (OuTSMART): a randomised controlled trial. EClin Med 2023;56:1–17. 10.1016/j.eclinm.2022.101819 - DOI - PMC - PubMed